| Q73644068 | A monthly period of symptoms associated with benign prostatic hyperplasia |
| Q44942064 | A single low dose of cadmium exposure induces benign prostate hyperplasia like condition in rat: A novel benign prostate hyperplasia rodent model. |
| Q46598165 | Antagonistic effect of Lepidium meyenii (red maca) on prostatic hyperplasia in adult mice |
| Q41684535 | Association between SRD5A2 rs523349 and rs9282858 Polymorphisms and Risk of Benign Prostatic Hyperplasia: A Meta-Analysis |
| Q37105061 | Association of a common variant at 10q26 and benign prostatic hyperplasia aggressiveness in han chinese descent |
| Q46474992 | Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer |
| Q47657497 | Benign growth of different prostate zones in aging men with slightly elevated PSA in whom prostate cancer has been excluded: a prospective study of 510 patients |
| Q41542467 | Benign prostatic enlargement is not associated with diabetes: a population-based study. |
| Q36610430 | Benign prostatic hyperplasia and subsequent risk of bladder cancer |
| Q37075987 | Benign prostatic hyperplasia: dietary and metabolic risk factors |
| Q47997299 | Changes in prostate-specific antigen levels and prostate volume in octogenarian men: community-based study |
| Q77732394 | Concurrent assessment of obstructive/irritative urinary symptoms and incontinence after radical prostatectomy |
| Q47152619 | Cone-beam CT findings during prostate artery embolization for benign prostatic hyperplasia-induced lower urinary tract symptoms: a case report |
| Q40601417 | Development of quantitative detection assays for CYR61 as a new marker for benign prostatic hyperplasia |
| Q36059979 | Does Inflammation Mediate the Obesity and BPH Relationship? An Epidemiologic Analysis of Body Composition and Inflammatory Markers in Blood, Urine, and Prostate Tissue, and the Relationship with Prostate Enlargement and Lower Urinary Tract Symptoms |
| Q46445221 | Effects of TAK-802, a novel acetylcholinesterase inhibitor, and tamsulosin, an alpha1-adrenoceptor antagonist, and their synergistic effects on the urodynamic characteristics in a guinea-pig model of functional bladder outlet obstruction |
| Q54580971 | Gene expression profiling of the human prostate zones. |
| Q44002659 | Genetic variants in 2q31 and 5p15 are associated with aggressive benign prostatic hyperplasia in a Chinese population |
| Q48607837 | Genetic variants in 5p13.2 and 7q21.1 are associated with treatment for benign prostatic hyperplasia with the α-adrenergic receptor antagonist |
| Q33769955 | Imaging of benign prostatic hyperplasia |
| Q81571865 | Increased expression of NKX3.1 in benign prostatic hyperplasia |
| Q34634768 | International Prostatic Symptom Score-voiding/storage subscore ratio in association with total prostatic volume and maximum flow rate is diagnostic of bladder outlet-related lower urinary tract dysfunction in men with lower urinary tract symptoms |
| Q28594176 | Isolation and characterization of mouse probasin: An androgen-regulated protein specifically expressed in the differentiated prostate |
| Q57559905 | Macronutrients, fatty acids, cholesterol, and risk of benign prostatic hyperplasia |
| Q37104427 | Metabolic factors associated with benign prostatic hyperplasia |
| Q42757693 | Metabolic syndrome and urologic diseases |
| Q44522571 | Mirabegron for male lower urinary tract symptoms |
| Q40071688 | Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest |
| Q44076974 | Nonsurgical management of benign prostatic hyperplasia in men with bladder calculi |
| Q80185150 | Obesity and benign prostatic enlargement: a large observational study in China |
| Q90387214 | Oral desmopressin in nocturia with benign prostatic hyperplasia: A systematic review of the literature |
| Q38637660 | Prostatic Artery Embolization (PAE) for Symptomatic Benign Prostatic Hyperplasia (BPH): Part 1, Pathological Background and Clinical Implications. |
| Q33737556 | Prostatic artery embolization as a primary treatment for benign prostatic hyperplasia: preliminary results in two patients. |
| Q38125607 | Prostatic artery embolization for enlarged prostates due to benign prostatic hyperplasia. How I do it. |
| Q33803807 | Randomized, controlled trial of laser vs. bipolar plasma vaporization treatment of benign prostatic hyperplasia |
| Q36413307 | Relationships between Prostate-Specific Antigen, Prostate Volume, and Components of Metabolic Syndrome in Healthy Korean Men. |
| Q39686642 | Risk behaviours and benign prostatic hyperplasia |
| Q53606267 | Risk factors for benign prostatic hyperplasia in South Korean men. |
| Q42002371 | Suppression of benign prostate hyperplasia by Kaempferia parviflora rhizome |
| Q34064723 | Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays |
| Q34492626 | Tamsulosin: an update of its role in the management of lower urinary tract symptoms |
| Q31032833 | Terazosin, doxazosin, and prazosin: current clinical experience |
| Q80803826 | The efficacy of transurethral resection of the prostate in the patients with weak bladder contractility index |
| Q48007367 | The histology of prostate tissue following prostatic artery embolization for the treatment of benign prostatic hyperplasia |
| Q40753387 | Thyroid and parathyroid hormones in benign prostatic hyperplasia |
| Q33198787 | Transurethral ultrasound applicators with directional heating patterns for prostate thermal therapy: in vivo evaluation using magnetic resonance thermometry |
| Q33821256 | Treatment of nocturia in the elderly |
| Q81160842 | Videourodynamic analysis of pathophysiology of men with both storage and voiding lower urinary tract symptoms |